NO-naproxen (AstraZeneca).
NO-naproxen, consisting of the NSAID naproxen linked to a nitric oxide (NO) moiety, is under development by AstraZeneca plc, under license from NicOx SA, for the potential treatment of acute/chronic pain.
Monck
Nat
N
Vernalis Research Ltd, Oakdene Court, 613 Reading Road, Winnersh, Wokingham, RG41 5UA, UK. n.monck@vernalis.com
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D009288:Naproxen / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009569:Nitric Oxide / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D020030:Nitric Oxide Donors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy*; D013329:Structure-Activity Relationship
D000894:Anti-Inflammatory Agents, Non-Steroidal; D020030:Nitric Oxide Donors; C111751:naproxen-n-butyl nitrate; D009569:Nitric Oxide; D009288:Naproxen